A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This open-label, non-randomized study will assess the mass balance, metabolism, routes and
rates of elimination as well as efficacy and safety of RO5185426 (RG7204; PLEXXIKON; PLX4032)
in previously treated or untreated patients with metastatic melanoma. Patients will receive
continuous twice daily oral treatment with RO5185426. On Day 15, a 14C-labeled dose will be
administered. Anticipated time on study treatment is until disease progression occurs.